Difference in treatment for metastatic bone tumors due to differences in opinion among departments - The role of medical teams for metastatic bone tumors

Daisuke Kikuchi, Toshiro Iizuka, Naohisa Yahagi, Hirotaka Maruno, Atushi Okazaki, Yusuke Takeda, Seizou Yamamoto, Hidetaka Kawabata, Masahiro Hayashi, Kazuma Kishi

Research output: Contribution to journalArticle

Abstract

Few experts can deal appropriately with metastatic bone tumors in the present situation. We developed a questionnaire about zoledronic acid for doctors with several specialties, and analyzed the differences in treatment strategy among various doctors retrospectively. Breast surgeons, have used zoledronic acid appropriately based on accurate knowledge, but it has been used inappropriately by doctors of other specialties due to lack of knowledge. Development of new treatment for metastatic bone tumors is awaited, but there is a possibility of inappropriate use as with zoledronic acid because of lack of knowledge and experience. So a medical team is necessary to provide the most recent knowledge of metastatic bone tumor and to enlighten other doctors.

Original languageEnglish
Pages (from-to)473-477
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number3
Publication statusPublished - 2010 Mar 6
Externally publishedYes

Keywords

  • Cancer board
  • Metastatic bone tumor
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Difference in treatment for metastatic bone tumors due to differences in opinion among departments - The role of medical teams for metastatic bone tumors'. Together they form a unique fingerprint.

Cite this